ResMed Reports Q1 Fiscal 2027 Growth Driven by Manufacturing Efficiency and GLP-1 Synergy
ResMed (RMD) reported its first quarter of fiscal year 2027 results, highlighting a 7% core revenue growth and a 50 basis point expansion in gross margins. The company attributed margin improvements to supply chain efficiencies and manufacturing productivity gains, supported by facility expansions in Indiana. Management identified a significant tailwind from the rise of GLP-1 weight-loss medications, noting that patients prescribed both GLP-1s and CPAP therapy are 11% more likely to initiate sleep apnea treatment. Additionally, ResMed utilized proceeds from the sale of its noncore MatrixCare software business to return over $1 billion to shareholders through dividends and share repurchases. The company maintains a positive long-term outlook, targeting high single-digit revenue growth and earnings growth that outpaces revenue due to operational leverage. Strategic focus remains on core medical devices, digital health software, and disciplined capital allocation.
Tickers: $RMD
Topics: divestiture GLP-1 impact gross margin expansion revenue growth share repurchases
Read the full article at Motley Fool
Part of the story ResMed Reports Q1 Fiscal 2027 Growth Driven by Manufacturing Efficiency and GLP-1 Synergy (4 articles)